-
CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus
•
HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim financial report for 2024, revealing a 5.4% year-on-year increase in revenues to HKD 6.05 billion (USD 776.7 million) in constant exchange rate terms. The profit attributable to the company’s owners surged 51.4% year-on-year to approximately…
-
China Grand Pharmaceutical Expands with Mitsubishi Tanabe Pharma and Baiji Pharma Acquisitions
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the completion of a 100% stake change registration for Mitsubishi Tanabe Pharma Corporation’s Tianjin subsidiary, as well as for compatriot firms Nanchang Baiji Medicine Technology Co., Ltd. and Jiangxi Bai’an Baiyu Pharmaceutical Technology Co., Ltd, collectively referred to…
-
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
•
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced a strategic partnership with MediTrust Health, an insurance, financing, and direct-to-patient pharmacy subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. This collaboration will focus on integrating Grand Pharma’s 90Y product into various commercial insurance schemes, aiming…
-
CGP’s GPN00884 Myopia Drug Enters Phase I Clinical Trial with First Patient Dosed
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the commencement of a Phase I clinical study for GPN00884, an innovative ophthalmic drug aimed at arresting the progression of childhood myopia, with the first patient now dosed. This randomized, double-blind, placebo-controlled, dose-escalation study is designed to evaluate…
